Pfizer shelves Beqvez, a Spark Therapeutics developed product
Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.
pharmaphorum4d
Pfizer drops Beqvez, leaving its gene therapy cupboard bare
Beqvez was Pfizer's first gene therapy, stemming from an alliance with Spark Therapeutics (now part of Roche) more than a ...
Pfizer’s bet on gene therapies in haemophilia has been a bust
Pfizer has ended the global commercialisation of its haemophilia B (factor IX deficiency) gene therapy Beqvez, citing soft ...
The Pharma Letter4d
Pfizer’s Beqvez decision lays bare gene therapy challenges
US pharma giant Pfizer has ended all development and commercialization activities relating to fidanacogene elaparvovec, a ...
hemophilianewstoday6h
Pfizer discontinues hemophilia B treatment Beqvez
Pfizer said it will discontinue gene therapy Beqvez (fidanacogene elaparvovec-dzkt), an approved hemophilia B treatment.
BioSpace1d
Vertex Severs Liver Gene Therapies Partnership with Verve
The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...
Global Advanced Therapy Medicinal Products Market to Grow Immensely at a CAGR of ~14% by 2032 | DelveInsight
DelveInsight's Advanced Therapy Medicinal Products Market Insights report provides the current and forecast market analysis, ...
hemophilianewstoday5h
What’s next after Pfizer’s gene therapy for hemophilia B is halted?
Columnist Jennifer Lynne assesses the effects of Pfizer's decision to halt production of its hemophilia B gene therapy, Beqvez.
DelveInsight Business Research, LLP: Global Advanced Therapy Medicinal Products Market to Grow Immensely at a CAGR of ~14% by 2032 | DelveInsight
The expansion of the advanced therapy medicinal products market is primarily fueled by the increasing incidence of chronic diseases. The rising prevalence of genetic disorders and cancer, along ...